News
ALEC
--
0.00%
--
H.C. Wainwright Sticks to Its Buy Rating for Alector (ALEC)
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Alector (ALEC) today and set a price target of $41.00. The company's shares closed last
SmarterAnalyst · 2d ago
Alector to Present at the BofA Securities 2021 Virtual Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer...
GlobeNewswire · 2d ago
Alector (ALEC) Has a New Rating from BTIG
BTIG analyst Thomas Shrader initiated coverage with a Buy rating on Alector (ALEC) yesterday and set a price target of $28.00. The company's shares closed
SmarterAnalyst · 3d ago
70 Biggest Movers From Yesterday
Gainers Nemaura Medical Inc. (NASDAQ: NMRD) shares surged 135.3% to close at $11.06 on Wednesday after the company receipt of a purchase order for 5,000 sugarBEAT transmitters and 200,000 sugarBEAT sensors from its U.K. licensee, DB Ethitronix Ltd.
Benzinga · 3d ago
Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates
Zacks.com · 3d ago
BRIEF-Alector Reports Q1 Loss Per Share Of $0.66
reuters.com · 3d ago
Alector EPS in-line, misses on revenue
Alector (ALEC): Q1 GAAP EPS of -$0.66 in-line.Revenue of $4.11M (-42.7% Y/Y) misses by $3.79M.Press Release
Seekingalpha · 3d ago
Alector, Inc. - Common Stock Q1 EPS $(0.66) Down From $(0.53) YoY, Sales $4.11M Down From $7.17M YoY
Alector, Inc. - Common Stock (NASDAQ:ALEC) reported quarterly losses of $(0.66) per share. This is a 24.53 percent decrease over losses of $(0.53) per share from the same period last year. The company reported $4.11
Benzinga · 3d ago
10-Q: ALECTOR, INC.
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 3d ago
Alector Reports 2021 First Quarter Financial Results and Provides Business Update
Enrollment ongoing for AL001 INFRONT-3 Phase 3 trial in frontotemporal dementia with a progranulin mutation and for AL002 INVOKE-2 Phase 2 trial in early...
GlobeNewswire · 3d ago
Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for
Zacks.com · 3d ago
Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Simply Wall St. · 4d ago
Morgan Stanley Sticks to Its Buy Rating for Alector (ALEC)
Morgan Stanley analyst Matthew Harrison maintained a Buy rating on Alector (ALEC) today and set a price target of $33.00. The company's shares closed last
SmarterAnalyst · 04/19 16:29
DJ Alector Price Target Raised to $33.00/Share From $31.00 by Morgan Stanley
Dow Jones · 04/19 13:19
DJ Alector Is Maintained at Overweight by Morgan Stanley
Dow Jones · 04/19 13:19
Morgan Stanley Maintains Overweight on Alector, Raises Price Target to $33
Morgan Stanley maintains Alector (NASDAQ:ALEC) with a Overweight and raises the price target from $31 to $33.
Benzinga · 04/19 13:09
Morgan Stanley Adjusts Price Target on Alector to $33 From $31, Maintains Overweight Rating
MT Newswires · 04/19 11:20
Replay: Investing in Alzheimer’s Treatment — Jupiter Orphan Therapeutics CEO Joins Fireside Chat
Christer Rosén, Chairman-CEO & Founder of Jupiter Orphan Therapeutics, Inc, Raymond “Scott” Turner MD, Professor Neurology, Georgetown University (Alzheimer’s scientist) and Mark Dant, Executive Director, Ryan Foundation IPO Edge, in partnership with The P...
IPO-Edge.com · 03/30 17:23
Alector to Present at Stifels 3rd Annual CNS Day
SOUTH SAN FRANCISCO, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating offic...
GlobeNewswire · 03/25 21:05
Investing in Alzheimers Treatment: Join Jupiter Orphan Therapeutics for Fireside Chat March 30
Christer Rosén, Chairman-CEO & Founder of Jupiter Orphan Therapeutics, Inc, Raymond “Scott” Turner MD, Professor Neurology, Georgetown University (Alzheimer’s scientist) and Mark Dant, Executive Director, Ryan Foundation IPO Edge, in partnership with The P...
IPO-Edge.com · 03/23 18:53
Webull provides a variety of real-time ALEC stock news. You can receive the latest news about Alector through multiple platforms. This information may help you make smarter investment decisions.
About ALEC
Alector, Inc. is a clinical-stage biopharmaceutical company focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a cause of multiple pathologies that are drivers of degenerative brain disorders. The Company is developing therapies designed to simultaneously counteract these pathologies by restoring healthy immune function to the brain. The Company's platform leverages large scale human genetic datasets, advanced tools in bioinformatics and imaging, and insights into neurodegeneration and immunology to identify immune system. Its platform focuses on target selection, biomarker selection and patient selection. Its product portfolio includes AL001, AL101, Al002 and AL003. Its AL001 targets frontotemporal dementia carrying a progranulin (FTD-GRN).